Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441311 | 0.93 | HPGD (0.55) | ALDH1A1DGAT1HPGDGAA | |
| SCHEMBL440637 | 0.89 | DGAT1 (0.53) | ALDH1A1DGAT1HPGDGAA | |
| SCHEMBL443296 | 0.88 | DGAT1 (0.48) | ALDH1A1TSHRDGAT1 | |
| SCHEMBL437986 | 0.85 | DGAT1 (0.55) | TSHRDGAT1HPGD | |
| SCHEMBL441604 | 0.85 | DGAT1 (0.54) | DGAT1HPGD | |
| SCHEMBL441098 | 0.85 | L3MBTL1 (0.55) | ALDH1A1DGAT1HPGDGAA | |
| SCHEMBL440582 | 0.84 | DGAT1 (0.54) | TSHRDGAT1 | |
| SCHEMBL441376 | 0.82 | DGAT1 (0.49) | ALDH1A1DGAT1HPGDGAA | |
| SCHEMBL14305144 | 0.82 | DGAT1 (0.53) | TSHRDGAT1 | |
| SCHEMBL439353 | 0.81 | DGAT1 (0.48) | DGAT1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | claimed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | claimed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | ALDH1A1 272/4885TSHR 2375/4885DGAT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.